Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 456 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... July 5, 2021 Seven Extra Years July 2, 2022 Load more HOT NEWS Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... Inequalities cause 2,000 extra cancer cases in Wales Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with... Is AI Ready to Play a Leading Role in Colorectal Cancer...
